Alterity Therapeutics (ASX:ATH) has enrolled the first patient in its Phase 2 clinical trial of ATH434, its lead candidate, in Italy.

Alterity Therapeutics says ATH434 is an oral agent designed to inhibit the aggregation of proteins implicated in neurodegeneration and has been granted Orphan designation for the treatment of Multiple System Atrophy (MSA).

It also says the Phase 2 trial is a randomised, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA and is expected to enroll approximately 60 adults.

The study will evaluate the effect of ATH434 treatment on neuroimaging and protein biomarkers, clinical endpoints, safety, and pharmacokinetics.